Morgan Stanley raised the firm's price target on Bicara Therapeutics to $37 from $36 and keeps an Overweight rating on the shares. The first quarter was focused on continued execution in FORTIFI-HN01, upcoming long-term Phase 1b data at ASCO, and further defining the development and commercial strategy for ficerafusp alfa, the analyst tells investors.
